Research
Research Interests
My research group focuses on understanding mechanisms that underlie cellular stress (especially Nrf2) responses in the context of drug toxicity and disease, and exploiting this knowledge to improve our ability to treat patients in a number of settings. We have a particular interest in liver disease and drug-induced liver injury, but are open to collaboration in other areas.
Check out all of my group's publications on PubMed and Google Scholar. Follow us on X/Twitter.
Some of our previous achievements in the areas of Nrf2 pharmacology and toxicology include:
# Demonstrating that pharmacological activation of Nrf2 can enhance liver regeneration following surgery - PubMed
# Revealing the transcriptional landscape of the Nrf2 pathway in primary human hepatocytes - PubMed
# Detailing the regulatory roles of Nrf2 in the kidney, in which Nrf2 inducers have recently emerged as novel therapeutic agents - PubMed
# Identifying a novel interaction between Keap1 and p62/SQSTM1, which regulates the degradation of Keap1 and activity of Nrf2 - PubMed
# Defining the chemical modification of sensor cysteine residues in Keap1 by Nrf2-activating compounds in living cells - PubMed
Examples of our current research include:
# Understanding the benefits and risks of modulating Nrf2 activity in different disease contexts.
# Establishing robust means of monitoring Nrf2 activity and its therapeutic modulation in patients.
# Determining the role of Nrf2 in drug toxicity and its value as a risk marker in the drug development process.
Group Members
Current group members (L-R):
# Giusy Russomanno (Post-doc)
# Hannah Coghlan (PhD student)
# Rob Young (PhD student)
# Olivia Harris (PhD student)
# Rowena Sison-Young (Post-doc/HLRF manager)
# Georgina Gregory (Post-doc)
# Karolina Kwiatkowska (PhD student; not shown)
# Ben Austin (Part-time technician; not shown)
In addition, since 2013 I have been primary supervisor for:
# 5 post-docs
# 7 PhD students
# 5 MRes students
# 1 MSc student
# +20 BSc research project students
Achievements of current/previous group members:
# 2024: Giusy Russomanno – Post-doc poster prize, British Toxicology Society annual congress.
# 2023: Hannah Coghlan – Oral communication prize, British Toxicology Society annual congress.
# 2023: Hannah Coghlan – EUROTOX Gordon Research Conference travel award.
# 2023: Giusy Russomanno – Poster prize, ISMIB Institute away day.
# 2022: Hannah Coghlan – Basic science presentation prize, Department postgraduate research day.
# 2022: Benjamin Chan – Oral communication prize, Association of Upper Gastrointestinal Surgeons annual scientific meeting.
# 2019: Lucia Livoti – Oral communication prize, British Toxicology Society annual congress.
# 2019: Benajmin Chan – Oral communication prize, Liverpool & North West Surgical Society annual meeting.
# 2019: Benjamin Chan – Oral communication prize, Association of Upper Gastrointestinal Surgeons annual scientific meeting.
# 2016: Olivia Matthews – British Pharmacological Society summer studentship.
Example destinations of previous group members:
# Tobias Bunday (PhD student) -> Translational Scientist, Sygnature Discovery
# Adedamola Olayanju (Post-doc) -> Senior Scientist, Manchester BIOGEL
# Fiona Mutter (PhD student) -> Post-doc, University of Greifswald, Germany
# Charles Winiarski (Post-doc) -> Business Development Manager, Manchester Inward Investment Agency
# Luke Shelton (PhD student) -> Post-doc, Radboud University Medical Center, the Netherlands
# Olivia Matthews (BPS undegraduate summer student) -> PhD student, University of Ediniburgh
Research grants
Cross sector experience award
THE ACADEMY OF MEDICAL SCIENCES (UK)
September 2024 - August 2025
Biomarker discovery to enable the non-invasive monitoring of NRF2 activator therapies in humans
INNOVATION LAUNCHPAD NETWORK+
September 2024 - February 2025
A new mechanism of redox regulation in Ser/Thr protein kinases
BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL
March 2023 - February 2026
A platform to support the pharmacological targeting of Nrf2 in humans
MEDICAL RESEARCH COUNCIL
January 2023 - December 2027
Unravelling species differences in stress responses to inform the selection, and reduce the use, of animals in preclinical drug safety testing
ASTRAZENECA LIMITED (UK)
October 2021 - September 2025
TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicines
EUROPEAN COMMISSION
January 2017 - August 2022
Preclinical evaluation of Nrf2 inhibition as a means to improve chemotherapeutic efficacy in patients with pancreatic cancer
PANCREATIC CANCER RESEARCH FUND (UK)
February 2016 - January 2020
Mechanistic investigation and risk:benefit analysis of the use of brusatol as a novel adjuvant for overcoming cisplatin resistance in bladder cancer
NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)
February 2016 - February 2018
Regulation of irinotecan anti-cancer pharmacology by Nrf2 – Implications for current use and potential for improved efficacy
NORTH WEST CANCER RESEARCH FUND
February 2014 - February 2016
Definition of chemical and molecular mechanisms of cytotoxicity induced by next-generation synthetic endoperoxide antimalarials, through the use of novel imaging-based approaches
ROYAL SOCIETY (CHARITABLE)
September 2011 - October 2011
Research collaborations
Prof Magnus Ingelman-Sundberg
Karolinska Institute
3D in vitro human liver models
Dr Tom Kensler
Fred Hutch Cancer Center
Nrf2 pharmacology & biomarker discovery
Dr Ciaran Fisher
GSK
Quantitative systems toxicology modelling of drug-induced liver injury
Prof Carolyn Young
Walton Centre
Pharmacodynamic biomarkers of Nrf2
Mr Steve Fenwick / Mr Hassan Malik / Mr Rob Jones / Mr Rafa Diez Neto
Aintree University Hospital
Human liver tissue and primary hepatocytes
Prof Andy Jones
Computational biology of stress response pathways
Prof Chris Goldring
Mechanisms and biomarkers of adverse drug reactions